Leniolisib

Phase 3

Pharming Group N.V. (PHAR)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in PIDs Linked to PI3K

View Full Landscape

Drug Information

Target Indication

PIDs Linked to PI3K

Clinical Trial

NCT06990529

Last updated: 1/22/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA5/21/2026

Joenja

Joenja is indicated for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) in adults and adolescents 12 years of age and older and weighing 45 kg or more.

Orphan

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

PHAR

Pharming Group N.V.

Pharmaceutical Preparations•Europe•NASDAQ

Related Pipeline

i.v. recombinant human C1 inhibitorPhase 3

Genetic Disorders

recombinant human C1 inhibitorPhase 3

Hereditary Angioedema

rhC1INHPhase 3

Hereditary Angioedema

RuconestPhase 2

Confirmed Coronavirus Disease

KL1333Phase 2

Primary Mitochondrial Disease

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts